Acute myeloid leukemia: open trials in Canada

23 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT05554406
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · University of Alberta Hospital, Edmonton · CSSS Champlain-Charles Le Moyne, Greenfield Park · QEII Health Sciences Centre/Nova Scotia Health Authority, Halifax · CIUSSSEMTL-Hopital Maisonneuve-Rosemont, Montreal · Jewish General Hospital, Montreal · Ottawa Hospital and Cancer Center-General Campus, Ottawa · University Health Network, Princess Margaret Hospital, Toronto · CancerCare Manitoba, Winnipeg
Registry updated 2026-11-06
NCT06317649
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
Jewish General Hospital, Montreal
Registry updated 2026-11-04
NCT06852222
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Queen Elizabeth II, Health Sciences Centre, Halifax · Juravinski Cancer Centre, Hamilton · London Health Sciences Centre · Victoria Hospital, London · CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont, Montreal · Princess Margaret Cancer Centre - University Health Network, Toronto · Vancouver General Hospital, Vancouver · CancerCare Manitoba, Winnipeg
Registry updated 2026-11-03
NCT05564390
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · University of Alberta Hospital, Edmonton · CSSS Champlain-Charles Le Moyne, Greenfield Park · QEII Health Sciences Centre/Nova Scotia Health Authority, Halifax · Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton · CIUSSSEMTL-Hopital Maisonneuve-Rosemont, Montreal · Jewish General Hospital, Montreal · Ottawa Hospital and Cancer Center-General Campus, Ottawa · Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto · University Health Network, Princess Margaret Hospital, Toronto · CancerCare Manitoba, Winnipeg
Registry updated 2026-11-02
NCT05554393
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · University of Alberta Hospital, Edmonton · CSSS Champlain-Charles Le Moyne, Greenfield Park · QEII Health Sciences Centre/Nova Scotia Health Authority, Halifax · Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton · CIUSSSEMTL-Hopital Maisonneuve-Rosemont, Montreal · Jewish General Hospital, Montreal · Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto · CancerCare Manitoba, Winnipeg
Registry updated 2026-10-28
NCT07155226
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Trial Treatment · Phase 1/2 · AstraZeneca
Montreal · Toronto
Registry updated 2026-10-23
NCT07211958
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Trial Treatment · Phase 3 · Syndax Pharmaceuticals
London · Montreal · Toronto
Registry updated 2026-10-21
NCT07007312
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Trial Treatment · Phase 3 · Kura Oncology, Inc.
Royal Victoria Hospital, Montreal · Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal · Gordon and Leslie Diamond Health Cancer Centre-Leukemia/BMT Program of BC, Vancouver
Registry updated 2026-10-13
NCT04065399
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Trial Treatment · Phase 1/2 · Syndax Pharmaceuticals
University Health Network, Toronto · The Hospital for Sick Children, Toronto
Registry updated 2026-10-09
NCT06376162
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Trial Treatment · Phase 1 · PedAL BCU, LLC
SickKids - The Hospital for Sick Children, Toronto
Registry updated 2026-10-09
NCT04256317
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Trial Treatment · Phase 2/3 · Taiho Oncology, Inc.
Eastern Health - Health Sciences Centre, St. John's · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-10-06
NCT07755202
Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia
Trial Treatment · Phase 2 · Florian Kuchenbauer
Vancouver General Hospital, Vancouver
Registry updated 2026-10-02
NCT04293562
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Trial Treatment · Phase 3 · Children's Oncology Group
Alberta Children's Hospital, Calgary · University of Alberta Hospital, Edmonton · IWK Health Centre, Halifax · McMaster Children's Hospital at Hamilton Health Sciences, Hamilton · Kingston Health Sciences Centre, Kingston · Children's Hospital, London · Centre Hospitalier Universitaire Sainte-Justine, Montreal · The Montreal Children's Hospital of the MUHC, Montreal · Children'S Hospital Of Eastern Ontario, Ottawa · CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Québec · Jim Pattison Children's Hospital, Saskatoon · Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke · Hospital for Sick Children, Toronto · British Columbia Children's Hospital, Vancouver · CancerCare Manitoba, Winnipeg
Registry updated 2026-09-17
NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Trial Treatment · Phase 2 · Cogent Biosciences, Inc.
University of Alberta Hospital, Edmonton · St. Michael's Hospital, Unity Health Toronto, Toronto
Registry updated 2026-09-15
NCT04726241
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Trial Treatment · Phase 1/2 · PedAL BCU, LLC
Alberta Children's Hospital, Calgary · University of Alberta Hospital, Edmonton · IWK Health Centre, Halifax · Children's Hospital, London · The Montreal Children's Hospital of the MUHC, Montreal · Centre Hospitalier Universitaire Sainte-Justine, Montreal · Children'S Hospital Of Eastern Ontario, Ottawa · CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Québec · Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke · Hospital for Sick Children, Toronto · British Columbia Children's Hospital, Vancouver · CancerCare Manitoba, Winnipeg
Registry updated 2026-08-25
NCT05702645
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
Research · Children's Oncology Group
This trial only enrols participants with Down syndrome
Children's Hospital, London
Registry updated 2026-08-25
NCT04093570
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Trial Treatment · Phase 2 · Taiho Oncology, Inc.
University of Alberta Hospital, Edmonton · QEII Health Sciences Centre, Nova Scotia · The Ottawa Hosptial, Ottawa · Princess Margaret Cancer Center, Toronto · Sunnybrook Health Sciences Centre, Toronto
Registry updated 2026-07-28
NCT07528417
Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
Trial Treatment · Phase 2 · University of Manitoba
CancerCare Manitoba, Winnipeg
Registry updated 2026-06-29
NCT06599762
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Trial Treatment · Phase 2 · University of Manitoba
CancerCare Manitoba, Winnipeg
Registry updated 2026-04-22
NCT07518654
Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma
Trial Treatment · Phase 1 · Michel Duval
CHU Sainte-Justine, Montreal · The Hospital for Sick Children, Toronto
Registry updated 2026-04-08
NCT04988555
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Trial Treatment · Phase 1/2 · Sumitomo Pharma America, Inc.
Tom Baker Cancer Center, Calgary · University of Alberta, Edmonton
Registry updated 2026-03-24
NCT06510868
Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
Research · University Health Network, Toronto
Princess Margaret Cancer Centre, Toronto
Registry updated 2026-03-05
NCT04260022
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Trial Treatment · Phase 1 · Ascentage Pharma Group Inc.
Princess Margaret Cancer Centre, Toronto
Registry updated 2025-11-05

All Acute myeloid leukemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error